Conference Day Two

Thursday, December 12, 2024

9:15 am Chair’s Opening Remarks

Constructing a Methodology of Target Selection to Ensure Efficiency of Strategy Whilst Prioritzing Innovation

9:30 am Panel Discussion: Curating a Target Selection Strategy With Adequate Risk Management to Maintain Investor Buy-In & Strategic Differentiation

Synopsis

  • Strategizing how to penetrate the dense ADC field whilst taking adequate risks in relation to target selection or ADC design
  • Understanding the degree of risk deemed acceptable by prospective investors to decide the target of choice
  • Considering scenarios appropriate to advance a novel ADC with a novel task, in a high risk approach

10:15 am Concluding the Decision-Making Process When Opting for Established or Novel Targets in Alignment With Your ADC in Question

  • Massimo Masiero Associate Director, Molecular Pharmacology, Bicycle Therapeutics

Synopsis

  • Proposing how you can leave your mark on the ADC space when utilizing traditional targets as opposed to a novel target approach
  • Concluding the current motivations across the ADC field: To be first-in-class or best-in-class
  • Brainstorming the lessons to be learned from traditional targets which can be applied to a novel target selection strategy

10:45 am Supercharging Mass Spectrometry Techniques to Identify ADC Targets Across Tumor & Healthy Cell Populations

  • Matthew Metzger Program, Alliance & Business Development Manager, Oxford BioTherapeutics

Synopsis

  • Leveraging multiple key elements to indicate target selection, including prevalence, individual patient marker abundance, and target copy number
  • Maximizing the chance of successful identification via thorough novel target validation steps to fully grasp the data collected
  • Generating in-depth data to analyze the future clinical efficacy and toxicity risk to be expected with a prospective target

11:15 am Morning Refreshments & Networking

Questioning the Importance of Payload & ADC Design on Target Dynamics to Optimize Selection

11:45 am Honing the Complex Relationship of the Payload–Linker–Target Triad to Ensure Alignment Between ADC Design & Target Selection

  • Zhu Chen Senior Vice President, Genmab

Synopsis

  • Triaging the role of the linker payload in target interaction to ensure peak ADC delivery and response
  • Highlighting the biological interaction between linker, payload and target antigen to direct the strategy and decision making
  • Prioritizing the stability of payload-linker binding in specific tumor environments to ensure functionality at the ADC target

12:15 pm Diagnosing the Risk of ADC Resistance Over Time, Focusing the Evolution of the Target in Response to Specific Payloads

Synopsis

  • Exploring the possibility of ADC target sub-clones expressing at the target cell in a response to specific ADC therapeutics
  • Diving into whether specific ADC designs lend themselves to target resistance which should be considered when deciding dosing schedules
  • Confirming whether resistance risk is a property which can be quantified in the target selection process

12:45 pm Roundtable Discussion: Highlighting the Importance of Target Antigen Biology as a Key Driver of ADC Success

  • Bill Mallet Senior Director, Target Validation, Bolt Biotherapeutics

Synopsis

  • Focusing the antigen as a functional target vs. payload delivery route to establish an allencompassing target selection strategy
  • Questioning whether antigen density (sites per cell) is an important parameter? Is rapid internalization essential?
  • How to select the best epitope / domain for ADC binding? Should immune effector potential (ADCC, ADCP) be strongly considered?

1:30 pm Lunch & Networking

Highlighting the Unique Challenges Faced When Identifying Bispecific Targets to Inform the Rationale Behind a Bispecific ADC Approach

2:30 pm Development of a Novel, Integrative Bioinformatics Approach for Bispecific Target Selection & Validation

Synopsis

  • Integrating expression profiles with antigen biology for improved target selection
  • Exploring preclinical efficacy data with novel bispecific agents with implications for disease positioning
  • Discussing the importance of bispecific selectivity for improved therapeutic index and addressing the challenges of demonstrating this in preclinical models

3:00 pm Panel Discussion: A Technical Deep Dive Into Antigen Selection for Bi-Specific ADCs

  • Bill Mallet Senior Director, Target Validation, Bolt Biotherapeutics
  • Mark Wappett Director - Bioinformatics, Almac Discovery
  • Dowdy Jackson Chief Executive Officer, Jackson Consulting Group

Synopsis

  • Outlining the criteria that is used to identify the best antigen pairs and the dynamic between the two chosen targets
  • Honing the binding affinities of each antigen and how these can be tuned accordingly for a specific ADC design
  • Brainstorming the target biology considerations to determine the format of the bispecific targets (e.g. 1:1 vs. 2:1)

3:45 pm Roundtable Discussion: The ADC Target White Space – What Does the Future Hold?

Synopsis

Unite as a community in an ultimate opportunity to celebrate the lessons learned over the past 3 days and discuss:

  • What are the key takeaways from the presentations and discussions at the summit?
  • How do we work more collaboratively as a community to drive progress?
  • Where should we be this time next year to classify it as successful?

4:30 pm Chair’s Closing Remarks

4:45 pm End of Scientific Program Day Two